Rubella virus E1 envelope glycoprotein (E1)

The **Rubella virus E1 envelope glycoprotein** is the main surface protein responsible for mediating viral entry into host cells via two critical roles: binding to a cell surface receptor and catalyzing the fusion of the viral envelope with host cell membranes[1][2][5][6]. E1 is a type I membrane protein, typically found as a glycosylated heterodimer with the E2 protein on the viral envelope[2][3]. Structurally, E1 is a class II viral fusion protein, characterized by a large membrane-fusion surface and unique metal-binding sites that are essential for its conformational changes and fusion activity, which occurs in a calcium-dependent manner at low pH typical of endosomal compartments[1][2][4][5][6]. This protein acts as the **sole target** for neutralizing antibodies during infection and vaccination, making it a critical antigen for immune protection[1][5][8]. Antibodies targeting the E1 glycoprotein can neutralize the virus by blocking its receptor-binding or membrane-fusion activities, preventing infection. E1 mutations can alter fusion properties and virus neutralization, which is relevant for viral adaptability and potential vaccine escape[4][7]. Rubella virus infection is typically mild in children but can cause severe congenital defects if acquired during pregnancy (congenital rubella syndrome). The E1 glycoprotein's critical functions make it a primary target for immune surveillance and vaccine-induced protection[1][5][8].

Other names

E1 glycoproteinRubella E1Rubella virus envelope protein E1

For vaccines: Induction of neutralizing antibodies that block receptor binding and membrane fusion functions of E1[1][5]